MedPath

Commons, Marty

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Phase 1
Completed
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
First Posted Date
2014-04-09
Last Posted Date
2024-12-11
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
225
Registration Number
NCT02108964
Locations
πŸ‡ΊπŸ‡Έ

Massachusetts General Hospital Mass General, Boston, Massachusetts, United States

πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Oncology Department, New York, New York, United States

πŸ‡¨πŸ‡³

Novartis Investigative Site, Taipei, Taiwan

Canadian Treat and Extend Analysis Trial With Ranibizumab

Completed
Conditions
wetAMD
Interventions
Other: 0.5 mg Ranibizumab intravitreal injections
First Posted Date
2014-04-04
Last Posted Date
2020-06-05
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
505
Registration Number
NCT02103738
Locations
πŸ‡¨πŸ‡¦

Novartis Investigative Site, Thetford Mines, Quebec, Canada

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

Phase 2
Terminated
Conditions
Primary Myelofibrosis
Interventions
First Posted Date
2014-03-19
Last Posted Date
2016-03-24
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
3
Registration Number
NCT02091752
Locations
πŸ‡ͺπŸ‡Έ

Novartis Investigative Site, Madrid, Spain

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients

Phase 1
Completed
Conditions
Rheumatoid Arthritis
Interventions
Biological: CFZ533
Drug: Placebo
First Posted Date
2014-03-17
Last Posted Date
2020-12-11
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
75
Registration Number
NCT02089087
Locations
πŸ‡¨πŸ‡³

Novartis Investigative Site, Taipei, Taiwan

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2014-03-17
Last Posted Date
2020-12-17
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
70
Registration Number
NCT02088684
Locations
πŸ‡ΊπŸ‡Έ

Sarah Cannon Research Institute Onc Dept, Nashville, Tennessee, United States

πŸ‡ΊπŸ‡Έ

University of Alabama at Birmingham/ Kirklin Clinic Dept Onc, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Dana Farber Cancer Institute Onc. Dept., Boston, Massachusetts, United States

and more 1 locations

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Phase 3
Completed
Conditions
Primary Myelofibrosis (MF)
Interventions
First Posted Date
2014-03-14
Last Posted Date
2016-07-11
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
51
Registration Number
NCT02087059
Locations
πŸ‡―πŸ‡΅

Novartis Investigative Site, Gifu, Japan

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Phase 2
Completed
Conditions
Cancer
Melanoma
Interventions
First Posted Date
2014-03-11
Last Posted Date
2022-02-01
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
77
Registration Number
NCT02083354
Locations
πŸ‡ΉπŸ‡­

Novartis Investigative Site, Songkla, Thailand

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Phase 1
Completed
Conditions
Chronic Myelogenous Leukemia
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Interventions
First Posted Date
2014-03-07
Last Posted Date
2024-03-18
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
326
Registration Number
NCT02081378
Locations
πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering, New York, New York, United States

πŸ‡ͺπŸ‡Έ

Novartis Investigative Site, Madrid, Spain

πŸ‡ΊπŸ‡Έ

Dana Farber Cancer Institute Hematology / Oncology, Boston, Massachusetts, United States

and more 4 locations

A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Phase 1
Completed
Conditions
AML and High Risk MDS
Interventions
First Posted Date
2014-03-05
Last Posted Date
2020-12-17
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
70
Registration Number
NCT02078609
Locations
πŸ‡³πŸ‡±

Novartis Investigative Site, Amsterdam, Netherlands

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Phase 1
Completed
Conditions
Neoplasms
Breast Neoplasms
Kidney Neoplasms
Pancreatic Neuroendocine Neoplasms (pNETs)
Interventions
First Posted Date
2014-03-04
Last Posted Date
2020-12-08
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
79
Registration Number
NCT02077933
Locations
πŸ‡¬πŸ‡§

Novartis Investigative Site, Manchester, United Kingdom

πŸ‡ΊπŸ‡Έ

Memorial Sloan Kettering Cancer Center SC - BYL719Z2102, New York, New York, United States

πŸ‡ΊπŸ‡Έ

Highlands Oncology Group, Fayetteville, Arkansas, United States

Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy